GB1388786A - Integral solid gel-lattice dosage form of high-moisture content - Google Patents

Integral solid gel-lattice dosage form of high-moisture content

Info

Publication number
GB1388786A
GB1388786A GB1130873A GB1130873A GB1388786A GB 1388786 A GB1388786 A GB 1388786A GB 1130873 A GB1130873 A GB 1130873A GB 1130873 A GB1130873 A GB 1130873A GB 1388786 A GB1388786 A GB 1388786A
Authority
GB
United Kingdom
Prior art keywords
lattice
gel
cellulose
histamine
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1130873A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Pharma Solutions Inc
Original Assignee
Catalent Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Pharma Solutions Inc filed Critical Catalent Pharma Solutions Inc
Publication of GB1388786A publication Critical patent/GB1388786A/en
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/025—Applications of microcapsules not provided for in other subclasses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1388786 Gel dosage unit R P SCHERER CORP 8 March 1973 [3 April 1972] 11308/73 Heading A5B Pharmaceutical dosage units consist of (a) a stable, inert, rigid, macromolecular gel-lattice which has been prepared by solidifying a melt and (b) within the interstices of the lattice a composition comprising (i) a pharmaceutically active compound and (ii) 4-20% of water based on the total weight of the dosage unit. The gel lattice may be gelatin, casein, collagen, albumin, soya protein, pecin, agar, acacia, karays, tragacanth, Irish moss, algins, alginates, guar, Iceland moss, modified starch, methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, sodium cellulose sulphate, polyvinylpyrrolidone, polyacrylic acid, copoly (ethylene/ maleic acid), polyvinyl alcohol. The pharmaceutically active compound may be: diphenhydramine hydrochloride (anti-histamine-somnifacient), phenolphthalein, (laxative), peppermintspearmint (breath freshner), ephedrine sulphate (decongestant), chloral hydrate (sedativesoporific), methorphan/cough remedy), isoproterenol hydrochloride (bronchodilator), dimenhydrinate (anti - nauseant), chlorpheniramine maleate (anti histamine).
GB1130873A 1972-04-03 1973-03-08 Integral solid gel-lattice dosage form of high-moisture content Expired GB1388786A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24083472A 1972-04-03 1972-04-03

Publications (1)

Publication Number Publication Date
GB1388786A true GB1388786A (en) 1975-03-26

Family

ID=22908131

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1130873A Expired GB1388786A (en) 1972-04-03 1973-03-08 Integral solid gel-lattice dosage form of high-moisture content

Country Status (5)

Country Link
JP (1) JPS5116926B2 (en)
CA (1) CA1041905A (en)
DE (1) DE2316242A1 (en)
FR (1) FR2179044B1 (en)
GB (1) GB1388786A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577213B2 (en) * 1985-12-19 1988-09-15 Capsoid Pharma Gmbh Process for producing shapes for administering individual doses
US4801460A (en) * 1986-04-11 1989-01-31 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
WO1999017744A1 (en) * 1997-10-07 1999-04-15 Fuisz Technologies Ltd. Immediate release drug delivery forms
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6221368B1 (en) 1996-09-13 2001-04-24 Basf Aktiengesellschaft Process for producing solid dosage forms by extrusion
WO2006125857A1 (en) * 2005-05-26 2006-11-30 Mika Tapio Reijonen Composition and manufacturing process of cetraria islandica based polymer blend
WO2009124763A3 (en) * 2008-04-10 2010-04-01 Biophil S.R.L. Dermal patch comprising chondrus crispus extract

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
IT1090710B (en) * 1976-12-01 1985-06-26 Merck & Co Inc IMPROVEMENT IN COMPOSITIONS FOR DRESSING SALADS AND SIMILAR
FR2515035A1 (en) * 1981-10-26 1983-04-29 Rhone Poulenc Sante NEW SOLID GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD OF MANUFACTURING THE SAME
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
DE4226753A1 (en) * 1992-08-13 1994-02-17 Basf Ag Preparations containing active substances in the form of solid particles
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
DE4446380A1 (en) * 1994-07-05 1996-01-11 Lohmann Therapie Syst Lts Hydrogel for the application of therapeutic and / or cosmetic agents to the skin
FR2725624B1 (en) * 1994-10-14 1997-01-17 Jouveinal Inst Rech PROCESS FOR THE PREPARATION OF CONTROLLED RELEASE PHARMACEUTICAL FORMS
GB9626152D0 (en) * 1996-12-17 1997-02-05 Cehmcolloids Ltd Encapsulation
WO1999024020A1 (en) * 1997-11-12 1999-05-20 The Dow Chemical Company A process for making a free-flowing, dust-free, cold water dispersible, edible, film-coating composition
AU8621398A (en) * 1998-01-12 1999-07-26 Buhler Ag Method and device for capsulating active ingredients

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577213B2 (en) * 1985-12-19 1988-09-15 Capsoid Pharma Gmbh Process for producing shapes for administering individual doses
US4801460A (en) * 1986-04-11 1989-01-31 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms
AU587897B2 (en) * 1986-04-11 1989-08-31 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5733574A (en) * 1989-11-07 1998-03-31 Dam; Anders Nicotine containing stimulant unit
US6110495A (en) * 1989-11-07 2000-08-29 Dam; Anders Nicotine containing stimulant unit
US6221368B1 (en) 1996-09-13 2001-04-24 Basf Aktiengesellschaft Process for producing solid dosage forms by extrusion
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
WO1999017744A1 (en) * 1997-10-07 1999-04-15 Fuisz Technologies Ltd. Immediate release drug delivery forms
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO2006125857A1 (en) * 2005-05-26 2006-11-30 Mika Tapio Reijonen Composition and manufacturing process of cetraria islandica based polymer blend
WO2009124763A3 (en) * 2008-04-10 2010-04-01 Biophil S.R.L. Dermal patch comprising chondrus crispus extract

Also Published As

Publication number Publication date
CA1041905A (en) 1978-11-07
FR2179044B1 (en) 1980-05-23
FR2179044A1 (en) 1973-11-16
JPS499480A (en) 1974-01-28
JPS5116926B2 (en) 1976-05-28
DE2316242A1 (en) 1973-12-06

Similar Documents

Publication Publication Date Title
GB1388786A (en) Integral solid gel-lattice dosage form of high-moisture content
EP0214735B1 (en) Controlled release pharmaceutical composition
US4792452A (en) Controlled release formulation
US4309404A (en) Sustained release pharmaceutical compositions
FI870588A0 (en) A process for preparing a sustained release solid dosage form
DE69636223D1 (en) FORMULATION WITH CONTROLLED RELEASE FOR WATER-LIQUEUTIC MEDICAMENTS IN WHICH A DISCHARGE OPENING IS MADE IN SITU
NO20065390L (en) Pharmaceutical preparation in solid unit dosage form
WO1996007398A3 (en) Sustained release of peptides from pharmaceutical compositions
YU31599A (en) Rapidly releasing and taste-masking pharmaceutical dosage form
CA2433186A1 (en) Delayed release pharmaceutical formulations
DE59806578D1 (en) Use of redispersible polymer powders or polymer granules for coating pharmaceutical or agrochemical dosage forms
ES8401977A1 (en) New cephem compounds, processes for preparation thereof and pharmaceutical composition containing them.
GR1003658B (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
Selzer et al. An experimental study of senecio poisoning in rats
DE59401833D1 (en) RETARDIC MICROTABLETTE OF BETA PHENYL PROPIOPHENONE DERIVATIVES
US4428951A (en) Long acting pharmaceutical composition
US6740340B1 (en) Pharmaceutical tablets comprising an NSAID and a prostaglandin
CA1225028A (en) Controlled release tablet
IE802033L (en) Dibenzazepine derivatives
ES8502076A1 (en) 3-Beta-(3'-(carboxypropionyloxy))-ursa-9(11),12-dience-28-carboxylic acid and its salts, process for its preparation and medicines containing these compounds.
CA2025663A1 (en) Indole derivatives
CN109568317B (en) Omeprazole compound preparation
ES2117557A1 (en) NEW PROCESS FOR PREPARING (-)-TRANS-N-p-FLUOROBENZOYLMETHYL-4-(p-FLUOROPHENYL)-3- 3,4-(METHYLENEDIOXY)PHENOXY]METHYL]-PIPERIDINE
GB1581912A (en) Compositions containing n-(2-amino-3,5-dibromo benzyl) - n -methyl-cyclohexylamine and/or its salts

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee